The treatment of pulmonary infections with Pseudomonas aeruginosa, the pathogen most responsible for morbidity and mortality in patients with cystic fibrosis (CF) (9) , remains an ongoing challenge. Despite the introduction of new antibiotics with marked in vitro activity against P. aeruginosa, the development of resistance during active treatment or with repeated use of a given antibiotic occurs all too frequently (3, 4, 7, (10) (11) (12) 16 ). Thus, new antibiotics for the treatment of P. aeruginosa infections are continually being developed by the pharmaceutical industry and tested in the clinical arena. Ciprofloxacin, aztreonam, and ceftazidime are all newer antibiotics that have been tested clinically in the treatment of pulmonary exacerbations of CF (4, 5, 7, 8, 15) . Each of these antibiotics has been shown to be clinically efficacious by traditional criteria, and all are in common clinical use at many centers caring for patients with CF.
Ciprofloxacin, aztreonam, and ceftazidime became available for clinical use at our institution in early 1985. Ceftazidime was marketed at that time, and ciprofloxacin and aztreonam were available in research protocols for patients with CF. This presented an opportunity to evaluate and monitor susceptibility patterns of P. aeruginosa isolates from our CF population and to study potential changes in susceptibility caused by the initial and continued use of these antibiotics. The objectives of this study were to evaluate patterns of susceptibility to ciprofloxacin, aztreonam, ceftazidime, and 7 other antipseudomonal antibiotics of P. aeruginosa isolates collected from our CF population before use, during the early stages of use, and later after introduction of the 3 new antibiotics and to study concomitant resistance patterns among these 10 antibiotics during those same time periods. who had received aztreonam (some received both), and 60 who had received neither. The vast majority of patients supplying organisms for this study were treated with ceftazidime. Other antibiotics in common clinical use during the study period were tobramycin, azlocillin, ticarcillin, and piperacillin.
Ciprofloxacin was the only antibiotic with which marked changes in MIC90s were associated. The MIC50, MIC90, and MIC range of ciprofloxacin for all isolates collected during the three time periods are presented in Table 1 . Changes in these values for the other antibiotics studied were generally not more than one dilution. The percentages of isolates from all three time periods that were susceptible to each antibiotic are presented in Table 2 . Rates of susceptibility to each antibiotic appeared to decline or remain stable with time, the exception being the rate for ticarcillin. The percentage of isolates susceptible to ticarcillin rose from 48 before introduction and clinical use of the three new antibiotics to 60% late after introduction. The percentages of isolates susceptible to each of the 10 antibiotics among isolates from patients treated with ciprofloxacin, with aztreonam, or with neither early and late after the introduction of the newer antibiotics were also determined (Table 3) . MICs varied only modestly. The rates of susceptibility to ciprofloxacin of isolates obtained from patients treated with ciprofloxacin fell from 95% before introduction to 84% during early clinical use and later rose to 95%. The rates of susceptibility to aztreonam of isolates obtained from patients treated with aztreonam rose from 76% before introduction to 82% during early clinical use and then fell to 61%. The percentage of isolates susceptible to ceftazidime (all patients) fell 14.3% from the period before introduction to the last study period ( Table 2 ). The occurrence of concomitant resistance of isolates collected during each of the time periods was determined. Although marked changes over time were not obvious, concomitant resistance to drugs with three groups, the cephalosporins, the penicillin derivatives, and aminoglycosides, was common. For example, among isolates collected during the final study period, more than half of those resistant to ceftazidime were also resistant to cefoperazone, and a similar percentage of those resistant to ticarcillin was also resistant to piperacillin. Ciprofloxacin-resistant isolates were resistant to the aminoglycosides one-third (tobramycin and amikacin) to one-half (gentamicin) of the time. DISCUSSION It appears that susceptibility rates of all isolates from the three study periods either declined or remained stable with time; the exception was ticarcillin, for which susceptibility rates rose. This latter observation may suggest that derepression of type I P-lactamase was responsible for at least some of the resistance observed in this study, since ticarcillin may be more stable to this type of enzyme.
The results are perhaps skewed by the fact that of the isolates included in the last time period (late after introduction), 60 were from patients who had never been treated with ciprofloxacin or aztreonam. The observation that susceptibility to all of the antibiotics studied was relatively high may suggest that resistance factors are not spread among patients with CF but are dependent on exposure to specific antibiotics. Susceptibility,rAtes of isolates collected from patients treated with ciprofloxacin appeared to remain high overall despite the continued use of this antibiotic (82% susceptible early during introduction and 95% susceptible late after introduction). Also, resistance to other antibiotics was higher in isolates exposed to ciprofloxacin in comparison with all isolates. Although this observation may suggest that ciprofloxacin induces widespread resistance among diverse classes of antibiotics, this seems unlikely to be the case since the major mechanism of resistance to ciprofloxacin appears to be through mutational alterations in the gyrA and gyrB genes of DNA gyrase, the target of quinolone antibacterial action (14) . A more likely explanation is that organisms from ciprofloxacin-treated patients, who were older, often had ANTIMICROB. AGENTS CHEMOTHER. more severe disease, and had been treated in the past with numerous other antibiotics, tended to already have marked resistance to other classes of antibiotics which had developed through intrinsic phenotypic mechanisms.
Susceptibility rates of isolates obtained from patients treated with aztreonam appeared to fall with the continued use of this antibiotic. Thus, our earlier observation that aztreonam resistance did not seem to develop rapidly during treatment (1) must be tempered with the knowledge that it does appear to emerge with repeated use of this agent. Most patients who sUpplied organisms for this study were treated with ceftazidime during the last two time periods. The decline in rates of susceptibility to this antibiotic was the greatest of those for all antibiotics, which may reflect the more extensive use of ceftazidime in our CF population.
Other investigators have reported problems of increasing resistance with this agent (7, 15) . Patterns of increasing resistance to aztreonam and ceftazidimie may lead to the use of these agents in combination treatment regimens. Although the rate of in vitro synergy between ceftazidime and the aminoglycosides appears to be low (17) , the rate for aztreonam-aminoglycoside combinations is comparable to that observed for aminoglycosides combined with various penicillin derivatives (2, 6) . It should be noted, however, that clinical response to antibiotic combinations has not been clearly shown to be superior to that obtained with singleagent therapy (6) .
Concomitant bacterial resistance was common within the various classes of antibiotics included in this study. Without identifying mechanisms of resistance, it is not possible to assess the occutrence of true cross-resistance among antibiotics. However, it is certainly possible that some true cross-resistance was present, since bacterial resistance to antibiotics not in use in our CF population (amikacin, cefoperazone, and gentamicin) was appreciable. Furthermore, one could certainly speculate that cross-resistance within a given class of antibiotics is likely. Mechanisms of development of resistance can take two forms in a study such as this. In each patient treated with repeated courses of one antibiotic, intrinsic ph,enotypic mechanisms of resistance are likely. However, with respect to the population as a whole (considering resistance in both patients treated with a given antibiotic and those not treated), plasmid-mediated resistance may also play a role. In fact, both general types of resistance are probably operative in explaining the resistance to individual antibiotics (or antibiotic classes) and concomitant resistance (among antibiotic classes) observed in this study. Although development of resistance in individual CF patients treated with repeated courses of one antibiotic is relatively common and therefore expected, it was of greater interest to note the presence of resistant isolates in patients treated only once or uiot at all with a given antibiotic.
The relative stability of the rate of susceptibility to ciprofloxacin of P. aeruginosa isolates from CF patients treated with ciprofloxacin at our institution is encouraging. It is hoped that, with the continued judicious use of this new agent, this will continue to be the case. However, the relatively lower rate of susceptibility of isolates from our patients not treated with ciprofloxacin merits close surveillance, as do the apparently declining rates of susceptibility to aztreonam and ceftazidime.
